课题基金 / 基金详情

Effects of electroconvulsive therapy on suicide in geriatrics patients with major depressive disorder: a nationwide cohort study using propensity score matching and instrumental variable analysis

Effects of electroconvulsive therapy on suicide in geriatrics patients with major depressive disorder: a nationwide cohort study using propensity score matching and instrumental variable analysis
电休克治疗对患有重度抑郁症的老年患者自杀的影响:一项使用倾向评分匹配和工具变量分析的全国性队列研究
批准号:
9886271
负责人:
SAMUEL WILKINSON
金额:
$12.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-05 至 2022-01-31

项目摘要

项目成果

SAMUEL WILKINSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Abstract The proposed study aims to determine the effect of ECT on completed suicides in geriatric patients with major depressive disorder (MDD). Data will be drawn from both the Medicare datasets and the National Death Index. To examine the effect of ECT on suicide, we will use an instrumental variables analysis, which accounts for unmeasured confounders, applied to propensity score-matched data. Prior to applying the propensity score model, patients will be individually matched on age, gender, number of antidepressant trials and medically treated suicide attempts in the preceding year. The instrumental variable will be the proportion of patients with MDD treated with ECT in each hospital in the prior calendar year; this instrument has been used successfully in a previous study of ECT and 30-day readmission risk. The primary outcome of the comparison will be completed suicide; secondary outcomes will include all-cause mortality. Suicide is a major public health crisis and, despite renewed efforts by public health leaders, the suicide rate has been increasing in the last 15 years. Most suicide victims suffer from treatable psychiatric disorders, most commonly a mood disorder such as MDD. ECT is the most effective treatment for MDD and professional guidelines recommend ECT as a treatment for severely ill patients with mood disorders who are at high risk of suicide. However, there is a critical gap in our understanding of the relationship between ECT and suicide; there has not been a convincing and consistent link between and reduced risk of completed suicide. The proposed study aims to fill this gap. Our study focuses on an enriched sample of geriatric patients, who experience particular benefit from ECT and are more likely than younger patients to receive the treatment. Additionally, this age group is historically at high risk for suicide. The proposed study is of central relevance to the NIMH mission of reducing suicide rates. Despite ECT being the most effective and definitive therapy for severe depression, it has been dogged by stigma for decades. However, the last several years have seen a surge in high-quality ECT research published in prominent journals reiterating the effectiveness of ECT, developing algorithms for predicting clinical outcomes, improving longer-term outcomes, showing its potential benefits on population health outcomes, and suggesting it is most cost-effective when used after a 2nd failed antidepressant trial. Given this resurgence of ECT research, the proposed study is both timely and of critical importance to reducing suicide rates. If, as hypothesized, ECT is shown to be associated with reduced rates of ECT, future research could aim to increase the dissemination of this critical treatment and study barriers to treatment access. Furthermore, the lack of a consistent link between ECT and reduced suicide rates is often used by anti-psychiatry/anti-ECT advocates to protest the use of the treatment. If ECT can convincingly be shown to be associated with lower rates of suicide, this may serve to galvanize suicide prevention groups to demand greater access to the treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
  • 批准号:
    10264145
  • 项目类别:
  • 资助金额:
    $57.55万
  • 财政年份:
    2020
  • 负责人:
    SAMUEL WILKINSON
  • 依托单位:
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
  • 批准号:
    10472036
  • 项目类别:
  • 资助金额:
    $96.9万
  • 财政年份:
    2020
  • 负责人:
    SAMUEL WILKINSON
  • 依托单位:
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
  • 批准号:
    10115267
  • 项目类别:
  • 资助金额:
    $60.22万
  • 财政年份:
    2020
  • 负责人:
    SAMUEL WILKINSON
  • 依托单位:
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
  • 批准号:
    10688291
  • 项目类别:
  • 资助金额:
    $96.6万
  • 财政年份:
    2020
  • 负责人:
    SAMUEL WILKINSON
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: